

John A Mcknight

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6326549/publications.pdf>

Version: 2024-02-01

66
papers

3,397
citations

159585

30
h-index

144013

57
g-index

68
all docs

68
docs citations

68
times ranked

5744
citing authors

#	ARTICLE	IF	CITATIONS
1	Estimated Life Expectancy in a Scottish Cohort With Type 1 Diabetes, 2008-2010. JAMA - Journal of the American Medical Association, 2015, 313, 37.	7.4	454
2	Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison. Diabetic Medicine, 2015, 32, 1036-1050.	2.3	273
3	Risk of Cardiovascular Disease and Total Mortality in Adults with Type 1 Diabetes: Scottish Registry Linkage Study. PLoS Medicine, 2012, 9, e1001321.	8.4	270
4	Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diabetes and Endocrinology, 2021, 9, 82-93.	11.4	251
5	Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes and Endocrinology, 2017, 5, 597-609.	11.4	248
6	Marked improvement in HbA1c following commencement of flash glucose monitoring in people with type 1 diabetes. Diabetologia, 2019, 62, 1349-1356.	6.3	116
7	Effect of a lifestyle intervention on weight change in south Asian individuals in the UK at high risk of type 2 diabetes: a family-cluster randomised controlled trial. Lancet Diabetes and Endocrinology, 2014, 2, 218-227.	11.4	110
8	External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants?. Diabetic Medicine, 2013, 30, 300-308.	2.3	97
9	Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission. Diabetes Care, 2018, 41, 341-347.	8.6	92
10	Supported Telemonitoring and Glycemic Control in People with Type 2 Diabetes: The Telescot Diabetes Pragmatic Multicenter Randomized Controlled Trial. PLoS Medicine, 2016, 13, e1002098.	8.4	77
11	N-Glycan Profile and Kidney Disease in Type 1 Diabetes. Diabetes Care, 2018, 41, 79-87.	8.6	75
12	Trends in type 2 diabetes incidence and mortality in Scotland between 2004 and 2013. Diabetologia, 2016, 59, 2106-2113.	6.3	71
13	Adaptor protein-2 sigma subunit mutations causing familial hypocalciuric hypercalcaemia type 3 (FHH3) demonstrate genotype-phenotype correlations, codon bias and dominant-negative effects. Human Molecular Genetics, 2015, 24, 5079-5092.	2.9	69
14	Effect of Socioeconomic Status on Mortality Among People With Type 2 Diabetes: A study from the Scottish Diabetes Research Network Epidemiology Group. Diabetes Care, 2011, 34, 1127-1132.	8.6	66
15	Rates of referable eye disease in the Scottish National Diabetic Retinopathy Screening Programme. British Journal of Ophthalmology, 2014, 98, 790-795.	3.9	64
16	Risk of acute kidney injury and survival in patients treated with Metformin: an observational cohort study. BMC Nephrology, 2017, 18, 163.	1.8	63
17	Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications. Diabetes Care, 2021, 44, 390-398.	8.6	55
18	End-stage renal disease and survival in people with diabetes: a national database linkage study. QJM - Monthly Journal of the Association of Physicians, 2015, 108, 127-134.	0.5	52

#	ARTICLE	IF	CITATIONS
19	Performance of Cardiovascular Disease Risk Scores in People Diagnosed With Type 2 Diabetes: External Validation Using Data From the National Scottish Diabetes Register. <i>Diabetes Care</i> , 2018, 41, 2010-2018.	8.6	47
20	Area-based socioeconomic status, type 2 diabetes and cardiovascular mortality in Scotland. <i>Diabetologia</i> , 2012, 55, 2938-2945.	6.3	45
21	Glycaemic control trends in people with type 1 diabetes in Scotland 2004–2016. <i>Diabetologia</i> , 2019, 62, 1375-1384.	6.3	45
22	Persistent C-peptide secretion in Type 1 diabetes and its relationship to the genetic architecture of diabetes. <i>BMC Medicine</i> , 2019, 17, 165.	5.5	43
23	Assessment of the effect of the COVID-19 lockdown on glycaemic control in people with type 1 diabetes using flash glucose monitoring. <i>Diabetic Medicine</i> , 2021, 38, e14374.	2.3	43
24	The emergence of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus amongst hospitalised immunocompromised patients in Scotland, November-December, 2009. <i>Eurosurveillance</i> , 2010, 15, .	7.0	43
25	Impact of deprivation on cardiovascular risk factors in people with diabetes: an observational study. <i>Diabetic Medicine</i> , 2008, 25, 194-199.	2.3	42
26	Assessment of the under-reporting of diabetes in hospital admission data: a study from the Scottish Diabetes Research Network Epidemiology Group. <i>Diabetic Medicine</i> , 2011, 28, 1514-1519.	2.3	42
27	Flash Glucose Monitoring is associated with improved glycaemic control but use is largely limited to more affluent people in a UK diabetes centre. <i>Diabetic Medicine</i> , 2017, 34, 732-732.	2.3	40
28	Preserved C-peptide secretion is associated with fewer low-glucose events and lower glucose variability on flash glucose monitoring in adults with type 1 diabetes. <i>Diabetologia</i> , 2020, 63, 906-914.	6.3	39
29	Culturally adapting the prevention of diabetes and obesity in South Asians (PODOSA) trial. <i>Health Promotion International</i> , 2014, 29, 768-779.	1.8	35
30	The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study. <i>Diabetologia</i> , 2019, 62, 621-632.	6.3	33
31	Achieved Levels of HbA1c and Likelihood of Hospital Admission in People With Type 1 Diabetes in the Scottish Population. <i>Diabetes Care</i> , 2011, 34, 1992-1997.	8.6	32
32	Comparison of serum and urinary biomarker panels with albumin/creatinine ratio in the prediction of renal function decline in type 1 diabetes. <i>Diabetologia</i> , 2020, 63, 788-798.	6.3	31
33	Ethnic Differences in Glycaemic Control in People with Type 2 Diabetes Mellitus Living in Scotland. <i>PLoS ONE</i> , 2013, 8, e83292.	2.5	30
34	Impact of routine clinic measurement of serum C-peptide in people with a clinician diagnosis of type 1 diabetes. <i>Diabetic Medicine</i> , 2021, 38, e14449.	2.3	28
35	International comparison of glycaemic control in people with type 1 diabetes: an update and extension. <i>Diabetic Medicine</i> , 2022, 39, e14766.	2.3	28
36	Predicting renal disease progression in a large contemporary cohort with type 1 diabetes mellitus. <i>Diabetologia</i> , 2020, 63, 636-647.	6.3	22

#	ARTICLE	IF	CITATIONS
37	Implementing a national quality assurance system for diabetes care: the Scottish Diabetes Survey 20012006. <i>Diabetic Medicine</i> , 2008, 25, 743-746.	2.3	21
38	Marked improvements in glycaemic outcomes following insulin pump therapy initiation in people with type 1 diabetes: a nationwide observational study in Scotland. <i>Diabetologia</i> , 2021, 64, 1320-1331.	6.3	19
39	Using Large Diabetes Databases for Research. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 1073-1078.	2.2	16
40	Cohort Profile: Scottish Diabetes Research Network Type 1 Bioresource Study (SDRNT1BIO). <i>International Journal of Epidemiology</i> , 2016, 46, dyw152.	1.9	15
41	Socioeconomic status and mortality in people with type 1 diabetes in Scotland 2006–2015: a retrospective cohort study. <i>Diabetic Medicine</i> , 2020, 37, 2081-2088.	2.3	14
42	Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology–Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium–Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Tj ETQq0 0 0 TgBT /Overlock 10	8.6	13
43	Type 2 diabetes, socioeconomic status and risk of cancer in Scotland 2001–2007. <i>Diabetologia</i> , 2013, 56, 1712-1715.	6.3	12
44	Factors associated with statin treatment for the primary prevention of cardiovascular disease in people within 2 years following diagnosis of diabetes in Scotland, 2006–2008. <i>Diabetic Medicine</i> , 2014, 31, 640-646.	2.3	12
45	HbA1c response and hospital admissions following commencement of flash glucose monitoring in adults with type 1 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001292.	2.8	12
46	Socioeconomic deprivation, technology use, C-peptide, smoking and other predictors of glycaemic control in adults with type 1 diabetes. <i>Diabetic Medicine</i> , 2021, 38, e14445.	2.3	12
47	Flash monitor initiation is associated with improvements in HbA1c levels and DKA rates among people with type 1 diabetes in Scotland: a retrospective nationwide observational study. <i>Diabetologia</i> , 2022, 65, 159-172.	6.3	12
48	Delay in starting insulin after failure of other treatments in patients with type 2 diabetes mellitus. <i>Hippokratia</i> , 2014, 18, 306-9.	0.3	11
49	The effect of DAFNE education, continuous subcutaneous insulin infusion, or both in a population with type 1 diabetes in Scotland. <i>Diabetic Medicine</i> , 2020, 37, 1016-1022.	2.3	9
50	Rising Rates and Widening Socioeconomic Disparities in Diabetic Ketoacidosis in Type 1 Diabetes in Scotland: A Nationwide Retrospective Cohort Observational Study. <i>Diabetes Care</i> , 2021, 44, 2010-2017.	8.6	8
51	Managing Acute Medical Admissions: The Plight of the Medical Boarder. <i>Scottish Medical Journal</i> , 2012, 57, 45-47.	1.3	7
52	Time trends in deaths before age 50 years in people with type 1 diabetes: a nationwide analysis from Scotland 2004–2017. <i>Diabetologia</i> , 2020, 63, 1626-1636.	6.3	6
53	The association of polypharmacy and high-risk drug classes with adverse health outcomes in the Scottish population with type 1 diabetes. <i>Diabetologia</i> , 2021, 64, 1309-1319.	6.3	5
54	Socioeconomic differences in cardiovascular disease risk factor prevalence in people with type 2 diabetes in Scotland: a cross-sectional study. <i>Diabetic Medicine</i> , 2020, 37, 1395-1402.	2.3	4

#	ARTICLE	IF	CITATIONS
55	Driving and hypoglycaemia: questions and answers. <i>Practical Diabetes</i> , 2012, 29, 13-14.	0.3	3
56	The design and evaluation of a self-management algorithm for people with type 1 diabetes performing moderate intensity exercise. <i>Practical Diabetes</i> , 2015, 32, 64-69.	0.3	3
57	Delayed hypoglycaemia in people with type 1 diabetes after performing moderate intensity exercise before the evening meal. <i>Practical Diabetes</i> , 2015, 32, 99-102.	0.3	3
58	Diabetes incidence in a high-risk UK population at 7 years: linkage of the Prevention of Diabetes and Obesity in South Asians (PODOSA) trial to the Scottish Diabetes Register. <i>Diabetic Medicine</i> , 2021, 38, e14369.	2.3	2
59	CSII from patient to politics; a national and local perspective. <i>British Journal of Diabetes and Vascular Disease</i> , 2012, 12, 91-96.	0.6	1
60	Can laboratory based research regarding type 1 diabetes and exercise be applied into the real-life environment?. <i>Practical Diabetes</i> , 2015, 32, 217-221.	0.3	1
61	Did the weight loss in the Prevention of Diabetes and Obesity in South Asians (PODOSA) trial differ by sex? An exploratory analysis. <i>Public Health</i> , 2017, 145, 67-69.	2.9	1
62	Diabetes in Scotland: a rising tide. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 375-376.	11.4	1
63	HbA1c Is Disproportionately Higher in Women and Older People With Type 1 Diabetes Compared With Flash Glucose Monitoring Metrics of Glycemic Control. <i>Journal of Diabetes Science and Technology</i> , 2022, 16, 446-453.	2.2	1
64	Diabetic papillopathy. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2002, 19, 24a-24a.	0.2	0
65	Management of diabetes in pregnancy. <i>Trends in Urology Gynaecology & Sexual Health</i> , 2008, 13, 32-35.	0.1	0
66	Substantial HbA1c Reduction Following Intermittent-Scanning Continuous Glucose Monitoring Was Not Associated With Early Worsening of Retinopathy in Type 1 Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2021, , 193229682199409.	2.2	0